Investing in Altria: A Reliable Option for Uncertain Markets

Dec.02.2022
Investing in Altria: A Reliable Option for Uncertain Markets
Investors seeking stability can look to tobacco giant Altria Group for reliable dividend income amid market volatility.

The volatile markets we witnessed in 2022 remind us of the importance of stability for investors. Retirees or others seeking dividends may want to consider investing in tobacco giant Altria Group (MO 0.92%) to stabilize their portfolio and put some money in their pockets.


This stock only dropped 4% in 2022 and paid a generous dividend yield of 8.5% to investors. As Wall Street enters 2023 with some uncertainty, the reliability of such a high yield may be more attractive to investors.


Altria may not be a suitable stock for everyone, but this is why those who hold it can sleep well at night knowing their investment is generating reliable dividend income.


During this period, the stock price fell by 32% as a result of Altria's disastrous failure after acquiring a stake in the e-cigarette company Juul for approximately $13 billion in 2018 and subsequently seeing its value evaporate due to regulatory scrutiny.


However, that was then; now, the stock of Altria reflects that mistake, with a price-to-earnings ratio (P/E) just above 9, significantly lower than the median P/E of the stock over the past decade (P/E of 17). This doesn't mean that the stock price can't still go down, but the discount on Altria's long-term fundamentals may provide a safety margin - bad news has already been factored in.


This may be one of the reasons why Altria is holding steady this year. I suspect that if the stock were traded at a higher valuation - for example, above its ten-year average - it would fall further in this bear market.


An 8.5% reliable dividend yield.


Since the 1960s, Americans have known that cigarettes are harmful to your health, but Altria has continued to make more money. In 2012, Altria shipped 136 billion units of tobacco products, while in 2021 they only shipped 95 billion units. However, the operating profit from tobacco products grew from $6.2 billion to $10.4 billion. This highlights Altria's pricing power due to the addictive nature of their products.


For years, these rising prices have supported Altria's financial health, making it a dividend king that has seen 52 consecutive years of increases.


YCharts provides data on the cash dividend payout ratio for MO.


Investors may be worried about the 81% dividend payout ratio, but they should not be overly concerned. Altria's business does not require a lot of capital; it can distribute the majority of profits to shareholders and still operate successfully. While the business may not be exciting, it has proven to be very effective in generating cash for investors.


Resting in an emergency situation.


It appears reasonable to assume that Altria's rinse-and-repeat model of raising prices will not be effective forever, and the management seems to understand this, as evidenced by their investments in Juul and Cronos Group in an attempt to diversify their business. Altria is still working towards creating a future beyond cigarettes, and investors should monitor their progress over the long term. However, if necessary, the company has significant leverage to generate additional cash.


Altria owns a 10% stake in global brewer AB InBev, which, based on today's stock price, is valued at approximately $11 billion. If Altria were to sell this stake, the resulting cash would be roughly one-eighth of Altria's market value, providing ample funds for stock buybacks or debt repayment. Altria could almost entirely pay off the debt it incurred when investing in Juul.


2FIRSTS will continue to track and report on this issue, with updates available on the "2FIRSTSAPP". Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

South Korea's Tobacco Plan Excludes 6-Methyl Nicotine as Customs Tightens Import Controls and Analog Liquid Imports Fall 83%
South Korea's Tobacco Plan Excludes 6-Methyl Nicotine as Customs Tightens Import Controls and Analog Liquid Imports Fall 83%
South Korea's government unveiled its first Tobacco Harm Management Basic Plan for 2027–2031 on October 29, 2026, proposing broader testing of vaping and heated tobacco products while excluding nicotine analogs such as 6-methyl nicotine. Synthetic nicotine came under tobacco regulation on April 24, and a June investigation found 6-methyl nicotine in 12 liquid inhalation products marketed as nicotine-free. Customs data released in September showed that imports of nicotine analog solutions fell 83.3%, from 12 metric tons in January–April to 2 metric tons in May–August. By September 20, imports had reached approximately 15 metric tons for the year, with 99.99% originating from China. Customs authorities have tightened pre-clearance testing and supply-chain documentation requirements, while the MFDS expects to complete its assessment of nicotine analog hazards by the end of 2026.
Regulations
Nov.04
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Philip Morris Japan (PMJ) launched Bold Ruby as a new regular color for the IQOS ILUMA i and IQOS ILUMA i ONE in Japan on September 16, 2026, priced at JPY 6,980 and JPY 3,980, respectively. Initial sales began through IQOS online and physical channels, with convenience stores and selected tobacco retailers set to follow from September 29. Bold Ruby is a regular rather than limited-edition colorway and is available for the ILUMA i and ILUMA i ONE, but not the ILUMA i PRIME. The release does not involve changes to the devices' core hardware or functions.
Sep.22
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
U.S. nicotine pouch startup Skoka Inc. has raised $21.5 million and committed $15 million to an FDA regulatory and scientific research program. Founder Dan Aziz previously built dietary supplement brand Premama, which was acquired by Dr. Reddy's Laboratories in 2023. Skoka is combining proprietary formulations, ingredient transparency and equity investment from professional athletes. The company submitted a bundled PMTA covering 55 products on October 1, 2026. Aziz said Skoka declined an opportunity to enter retail in 2025, prioritizing product research and regulatory submissions instead. It now targets a U.S. retail launch in 2027, subject to FDA requirements. Its products have not received marketing authorization.
Business
Nov.04
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07